Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

FMCG stocks sizzle
Thu, 4 Dec 01:30 pm

Indian share markets firmed up in the post-noon trading session. Barring consumer durables, IT and realty, all the stocks are trading in the green. FMCG and capital goods stocks are the biggest gainers today.

BSE-Sensex is up 92 points and NSE-Nifty is trading 11 points up. BSE Mid Cap is trading 0.4% up and BSE Small Cap index is trading up by 0.5%. The rupee is trading at 61.94 to the US dollar.

Food & tobacco stocks are trading mixed with ITC and Godfrey Phillips being the major gainers whereas Golden Tobacco and Tata Coffee are among major losers. As per a leading financial daily, the government has shelved the Cigarette and Other Tobacco Products (Amendment) Bill aimed at making restrictions on cigarette sales more stringent. This comes as a relief to cigarette manufacturing companies as until 25th November, the government had indicated that it wanted to go ahead with the anti-smoking legislation that included curbs on loose sale of cigarettes and raising the age bar and fines on public smoking. The move has been on account of the adverse impact of the stringent laws on the tobacco growing farmers of Andhra Pradesh and areca nut growers of Andhra Pradesh. Since many farmers in the country are still dependant on these two cash crops, it was decided that the bill should not be introduced until the farmers shifted to alternative crops. As this is not likely to happen in the near future, the bill has been shelved indefinitely.

Domestic pharma stocks are trading mixed with Wockhardt and J B Chemicals being the major gainers whereas Indoco Remedies and IPCA Labs are trading in the red. As per a leading financial daily, Germany has barred Ranbaxy Laboratories from exporting antibiotic cephalosporin to its country. This development comes after a non-compliance report issued by the German regulator post inspection in June. As per the report, deficiencies were observed in the operation of drug manufacturing rooms and procedures in sterilization of equipment at Ranbaxy's Dewas plant. The company's Dewas factory along with the other India-based plants have already been barred from exporting to US. Reportedly, Ranbaxy derives more than 50% of its revenues from the US. Germany accounted for 2% of the company's global sales during the 15-month period ended March 2014. The company, which has been acquired by Sun Pharma, has been working towards getting the regulatory bans lifted. Ranbaxy stock is trading down 0.9%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "FMCG stocks sizzle". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.